Blue­bird says it has more good news for its gene ther­a­py safe­ty, but a pric­ing dis­agree­ment in Ger­many will spur lay­offs

Fol­low­ing two safe­ty scares back in Feb­ru­ary re­gard­ing its sick­le-cell pro­gram, blue­bird bio’s gene ther­a­py ap­pears to be in the clear.

Ex­ecs from the Cam­bridge, MA-based biotech pro­vid­ed an­oth­er up­date on Lenti­Glo­bin safe­ty con­cerns Tues­day morn­ing, this time re­gard­ing a pa­tient who was thought to have de­vel­oped a case of myelodys­plas­tic syn­drome. Af­ter fur­ther analy­ses and test­ing, in­ves­ti­ga­tors have re­vised the di­ag­no­sis to trans­fu­sion-de­pen­dent ane­mia and ruled that it is not an in­ci­dent of the blood can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER